Decipher Labs Ltd (DECIPHER)

Loading page…

Decipher Labs Ltd (DECIPHER) · mywealthgrid

About

Decipher Labs Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹6 Cr

P/E

—

P/B

0.7×

Dividend yield

ROE

-19.8%

ROCE

-23.7%

Debt / equity

0.06

OPM

-24.1%

EPS (TTM)

₹-5.0

Book value

₹8.2

52-week high

—

52-week low

—

2,099 historical price candles were omitted because the exchange source has not been verified.

₹6.0-2.4%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0.1)

Cons

−Low return on equity of -16.7% (3-yr avg)
−Revenue shrank over the last 5 years (-24% a year)
−Low promoter holding of 16.4%

Research score

Structured signal from quality, growth, valuation and momentum.

41/100

Business quality: 24
Growth: 0
Valuation: 100

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	56	65	46	36	23	14
COGS	0	0	1	3	1	1
Gross profit	—	—	45	33	22	13
	52	59	53	34	29	17
	3	6	-8	-1	-7	-3
OPM %	6.2%	9.2%	-18.5%	-2.7%	-32%	-24.1%
Depreciation	1	1	0	0	0	1
Interest	1	0	0	0	0	0
	1	8	5	0	1	0
Profit before tax	2	12	-4	-1	-6	-4
Tax	1	1	-1	0	-1	-1
Tax %	34.6%	7.9%	-35.6%	38%	-20.5%	-16.3%
	1	11	-3	-2	-5	-3
PAT margin %	2.5%	17.4%	-5.9%	-4.7%	-22.5%	-21.9%
EPS (₹)	—	—	—	-1.7	-5	-3.1
EPS adjusted (₹)	1.4	11.3	-2.7	-1.7	-5	-3.1
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	10	10	10	10	10	10	10
Reserves	2	4	14	13	12	13	-2
	16	9	10	1	0	0	1
	7	16	7	4	12	3	0
Total equity & liabilities	35	39	42	28	34	26	9
	3	0	3	3	3	3	0
CWIP	—	—	—	—	—	0	—
Investments	—	0	0	4	5	0	9
	32	38	39	21	25	23	0
Total assets	35	39	42	28	34	26	9

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	0	-15	2	8	-2	5	-10	-2
	-0	-0	-0	-0	-4	-2	3	-0
	0	16	4	1	-2	-1	0	0
Net cash flow	0	1	6	9	-8	2	-7	-2
Free cash flow	0	-15	2	8	-2	5	-10	-2
CFO / Operating profit %	—	—	53%	137%	—	—	—	—

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	98.9%	91.2%	97%	95.4%
EBITDA margin %	6.2%	9.2%	-18.5%	-2.7%	-32%	-24.1%
EBIT margin %	4.7%	7.9%	-19.4%	-3.9%	-34.1%	-27.8%
PAT margin %	2.5%	17.4%	-5.9%	-4.7%	-22.5%	-21.9%
Working capital
Receivable days	77	71	79	79	68	1
Inventory days	0	0	0	0	0	0
Payable days	22	14	859	580	632	56
NWC days	55	57	-780	-501	-564	-55
Leverage
Current ratio	1.3	3.44	4.05	2.1	7.23	0.23
Debt to EBITDA	2.54	1.71	—	—	—	—
Debt to equity	0.64	0.43	0.04	0	0.01	0.06
Interest coverage	2.9	26.8	-3.5	-4.5	—	—
Asset turnover	1.43	1.56	1.62	1.07	0.88	1.56
Return ratios
Return on assets %	3.6%	27.1%	-9.5%	-5%	-19.7%	-34.2%
Return on capital employed %	15.3%	49.1%	-5.5%	-4.4%	-28.6%	-23.7%
Return on equity %	10.2%	47.1%	-11.5%	-7.7%	-22.2%	-37.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%	16.43%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%	83.57%
No. of shareholders	—	—	—	—	—	—	—	—	30,174	29,825	29,596	29,368

Promoter holding up 0 percentage points since Sep 2023.

126 deals · 6 Dec 2021 – 12 Jun 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
12 Jun 2024	MEHULKUMAR NATUBHAI PANUCHA	Bulk	BSE	Buy	1,44,337	₹24.12	₹0.35 Cr
12 Jun 2024	MEHULKUMAR NATUBHAI PANUCHA	Bulk	BSE	Sell	1,06,382	₹23.26	₹0.25 Cr
12 Jun 2024	KRUNALKUMAR KANUJI THAKOR	Bulk	BSE	Sell	73,134	₹24.00	₹0.18 Cr
12 Jun 2024	VINAY KUMAR PRODDATUR	Bulk	BSE	Sell	57,052	₹21.18	₹0.12 Cr
12 Jun 2024	VINAY KUMAR PRODDATUR	Bulk	BSE	Buy	57,052	₹23.94	₹0.14 Cr
12 Jun 2024	KRUNALKUMAR KANUJI THAKOR	Bulk	BSE	Buy	7,634	₹23.88	₹0.02 Cr
11 Jun 2024	KRUNALKUMAR KANUJI THAKOR	Bulk	BSE	Buy	66,032	₹19.20	₹0.13 Cr
11 Jun 2024	KRUNALKUMAR KANUJI THAKOR	Bulk	BSE	Sell	532	₹18.00	₹0.00 Cr
15 May 2024	RAJESH MANUBHAI SHAH	Bulk	BSE	Sell	71,000	₹14.94	₹0.11 Cr
2 Jan 2024	LAKHUBHA SOLANKI	Bulk	BSE	Sell	68,968	₹21.12	₹0.15 Cr

1–10 of 126

1 / 13

Mr. VENKATESWARA RAO GUDIPUDINon-Executive - Independent Director-Chairperson
Mr. SUSHANT MOHAN LALNon-Executive - Non Independent Director
Mr. JANAKIRAM AJJARAPUNon-Executive - Non Independent Director
Mrs. Sonam JalanChief Financial Officer
Mrs. LAKSHMI VIJAYA NIMMALANon-Executive - Independent Director
Mrs. GAYATHRI RAGHURAMNon-Executive - Independent Director
Mr. DALAVATH AMARSINGHExecutive Director
Ms. Preeti SinghCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Decipher Labs Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results13 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

15 announcementsExport CSV

30 Sept 2026, 2:39 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

30 Sept 2026, 2:36 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

29 Sept 2026, 10:43 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

9 Sept 2026, 2:29 pmCompany Update

Newspaper Advertisement For AGM Notice For The Financial Year 2025-26.

General PDF

8 Sept 2026, 5:36 pmAGM/EGM

Intimation Of Book Closure And Cut Off Date For Annual General Meeting

AGM PDF

8 Sept 2026, 5:34 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

8 Sept 2026, 5:30 pmAGM/EGM

Notice Of 40Th Annual General Meeting For The Financial Year 2025-26 Under Regulation 34 Of SEBI (LODR) Regulation 2015.

AGM PDF

5 Sept 2026, 6:59 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

Date	Category	Subject	Filing
30 Sept 2026, 2:39 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 2:36 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	98.9%	91.2%	97%	95.4%
EBITDA margin %	6.2%	9.2%	-18.5%	-2.7%	-32%	-24.1%
EBIT margin %	4.7%	7.9%	-19.4%	-3.9%	-34.1%	-27.8%
PAT margin %	2.5%	17.4%	-5.9%	-4.7%	-22.5%	-21.9%
Working capital
Receivable days	77	71	79	79	68	1
Inventory days	0	0	0	0	0	0
Payable days	22	14	859	580	632	56
NWC days	55	57	-780	-501	-564	-55
Leverage
Current ratio	1.3	3.44	4.05	2.1	7.23	0.23
Debt to EBITDA	2.54	1.71	—	—	—	—
Debt to equity	0.64	0.43	0.04	0	0.01	0.06
Interest coverage	2.9	26.8	-3.5	-4.5	—	—
Asset turnover	1.43	1.56	1.62	1.07	0.88	1.56
Return ratios
Return on assets %	3.6%	27.1%	-9.5%	-5%	-19.7%	-34.2%
Return on capital employed %	15.3%	49.1%	-5.5%	-4.4%	-28.6%	-23.7%
Return on equity %	10.2%	47.1%	-11.5%	-7.7%	-22.2%	-37.4%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Decipher Labs Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Ratio timeline

Board meetings1

No fund holdings on record

Announcements

Annual reports

Not in the F&O segment

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1